PTC Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
PR Newswire - Tue May 06, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the first quarter ended March 31, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
PTC Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Wed Apr 23, 3:30PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at two upcoming investor conferences:
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2014 Financial Results
PR Newswire - Tue Apr 22, 3:30PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2014 financial results on Tuesday, May 6, 2014 at 4:30 p.m. (ET) after the closing of the market.
PTC Therapeutics grants stock option to four new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Tue Apr 22, 5:04AM CDT
Biopharmaceutical company PTC Therapeutics (NasdaqGS
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Mon Apr 21, 12:00PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 17, 2014 it granted non-statutory stock options to purchase an aggregate of 9,800 shares of its common stock to four new employees. The grant was made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
Why PTC Therapeutics, Inc. Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 12:37PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of PTC Therapeutics , a biopharmaceutical...
PTC Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
PR Newswire - Thu Mar 06, 3:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
PTC Therapeutics To Present At The Cowen & Company 34th Annual Health Care Conference
PR Newswire - Fri Feb 28, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care Conference on Wednesday, March 5th at 9:20 am ET at the Marriott Copley Plaza Hotel in Boston.